Supplementary Tables – Efficacy and Safety of First-Line Therapies in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis

Table A1. Full search strategy for Embase. Table A2. Full search strategy for MEDLINE. Table A3. Full search strategy for Cochrane. Table A4. Trials identified from the SLR (n=57). Table A5. PFS evidence for overall EGFRm+ NSCLC patient population, by mutation type, and by geographical region. Table A6. OS evidence for overall EGFRm+ NSCLC patient population. Table A7. Base case PFS - pairwise comparisons of all interventions and comparators. Table A8. Base case OS - pairwise comparisons of all interventions and comparators.

表A1：Embase数据库完整检索策略。表A2：MEDLINE数据库完整检索策略。表A3：Cochrane数据库完整检索策略。表A4：从系统文献综述（Systematic Literature Review, SLR）中识别出的试验（n=57）。表A5：按突变类型及地理区域划分的表皮生长因子受体突变阳性非小细胞肺癌（EGFR mutation-positive non-small cell lung cancer, EGFRm+ NSCLC）整体患者人群的无进展生存期（Progression-Free Survival, PFS）证据。表A6：表皮生长因子受体突变阳性非小细胞肺癌（EGFRm+ NSCLC）整体患者人群的总生存期（Overall Survival, OS）证据。表A7：基准情形下的无进展生存期（PFS）——所有干预措施与对照措施的配对比较。表A8：基准情形下的总生存期（OS）——所有干预措施与对照措施的配对比较。